Ameriprise
EIGR

Ameriprise’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Ameriprise’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-250,178
Closed -$1.25M – 3984
2024
Q1 		$1.25M Sell
250,178
-7
-0% -$43 ﹤0.01% 3079
2023
Q4 		$1.68M Sell
250,185
-36,231
-13% -$319K ﹤0.01% 2956
2023
Q3 		$2.62M Hold
286,416
– – ﹤0.01% 2690
2023
Q2 		$6.05M Buy
286,416
+18,832
+7% +$580K ﹤0.01% 2194
2023
Q1 		$7.2M Buy
267,584
+86,092
+47% +$4M ﹤0.01% 2040
2022
Q4 		$6.43M Sell
181,492
-87,651
-33% -$10.5M ﹤0.01% 2105
2022
Q3 		$60.8M Buy
269,143
+13,290
+5% +$3.27M 0.02% 624
2022
Q2 		$48.4M Buy
255,853
+6,018
+2% +$1.21M 0.02% 732
2022
Q1 		$62.2M Buy
249,835
+15,011
+6% +$2.37M 0.02% 709
2021
Q4 		$36.6M Buy
234,824
+37,835
+19% +$7.32M 0.01% 987
2021
Q3 		$39.5M Buy
196,989
+13,155
+7% +$3.13M 0.01% 878
2021
Q2 		$47M Buy
183,834
+35,493
+24% +$8.86M 0.01% 825
2021
Q1 		$39.4M Buy
148,341
+17,613
+13% +$5.55M 0.01% 886
2020
Q4 		$48.2M Buy
130,728
+84,326
+182% +$24.2M 0.02% 752
2020
Q3 		$11.3M Buy
+46,402
New +$14.4M ﹤0.01% 1470

Other funds holding EIGR

PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Ameriprise's EIGR Position: Q2 2024 in Review

Ameriprise sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2024, closing a stake of 250,178 shares — an estimated $1.25M sold.

Ameriprise first reported a position in EIGR in Q3 2020 and held it in 15 quarters. The position peaked at $62.2M in Q1 2022. 2 funds tracked by Wall St. Rank hold EIGR as of Q2 2024.

  • Ameriprise reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
  • Ameriprise sold 250,178 Eiger BioPharmaceuticals, Inc. shares in Q2 2024, an estimated $1.25M.
  • Ameriprise first reported a position in Eiger BioPharmaceuticals, Inc. in Q3 2020 and held it in 15 quarters.
  • Ameriprise's Eiger BioPharmaceuticals, Inc. position peaked at $62.2M in Q1 2022.
  • 2 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2024.

Based on Ameriprise's 13F filing for Q2 2024, filed 14 Aug 2024.